- PharmaDrug (PHRX) has formed a research collaboration with Terasaki Institute for a novel ocular drug formulation program to deliver DMT and other tryptamines to treat eye disease
- PharmaDrug will focus on developing a novel ocular drug delivery platform to deliver DMT and other undisclosed tryptamines
- This will be a potential therapeutic solution in treating the significant unmet medical needs of glaucoma patients
- The global market for glaucoma was estimated by Market Scope at $4.8 billion in 2019 with the U.S. market representing $1.9 billion
- PharmaDrug, working with the renowned Terasaki Research Institute, has entered into a sponsored research agreement that will evaluate multiple candidate tryptamines
- PharmaDrug Inc. (PHRX) is up 9.09 per cent and is trading at C$0.06 at 11:34 pm PT
PharmaDrug Inc. (PHRX) has entered into a sponsored research agreement with the Terasaki Institute.
Under the agreement, PharmaDrug and The Terasaki Institute will develop a novel ocular drug delivery platform that aims to deliver psychedelic and tryptamine-based pharmaceuticals, such as N, N-dimethyltryptamine, for eye diseases.
PharmaDrug will focus on developing a novel ocular drug delivery platform to deliver DMT and other undisclosed tryptamines as a potential therapeutic solution in treating the significant unmet medical needs of glaucoma patients.
Glaucoma is a disorder of the optic nerve that results in irreversible vision loss and is the second leading cause of blindness in the world, according to the World Health Organization.
Glaucoma impacts more than 2.7 million people aged 40 or older in the United States and current treatments are known to have poor rates of compliance of up to 80 per cent of patients.
The global market for glaucoma was estimated by Market Scope at $4.8 billion in 2019 with the U.S. market representing $1.9 billion.
PharmaDrug, working with the renowned Terasaki Research Institute, will evaluate multiple candidate tryptamines, including DMT in various preclinical models of glaucoma.
Studies will include cell-based basic research, active pharmaceutical ingredient formulation, and exploitation of novel delivery technologies aimed at improving patient outcomes while reducing side effects.
The Terasaki Institute for Biomedical Innovation is a biotechnology institute that develops medical devices and cutting-edge protocols for a variety of diagnostic, monitoring and treatment applications. Their research platforms include work in biomaterials, cellular and tissue engineering, wearable biosensors and organs-on-a-chip, with specific expertise in novel polymer development.
“This relationship will expedite our development plan and move us meaningfully closer to our goal of evaluating DMT and other tryptamines for various types of eye disease which require both a pharmacological and delivery solution to fill the significant treatment gap in glaucoma,” said Daniel Cohen, Chairman and CEO of PharmaDrug.
PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs.
PharmaDrug Inc. (PHRX) is up 9.09 per cent and is trading at C$0.06 at 11:34 pm PT.
